| Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma M Crump, S Leppä, L Fayad, JJ Lee, A Di Rocco, M Ogura, H Hagberg, ... J Clin Oncol 34 (21), 2484-2492, 2016 | 126 | 2016 |
| A first-in-human phase I study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 dimesylate), in patients with advanced cancer A Patnaik, P Haluska, AW Tolcher, C Erlichman, KP Papadopoulos, ... Clinical Cancer Research 22 (5), 1095-1102, 2016 | 106 | 2016 |
| Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter … W Wick, JP Steinbach, M Platten, C Hartmann, F Wenz, A Von Deimling, ... Neuro-oncology 15 (10), 1405-1412, 2013 | 67 | 2013 |
| Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in … JW Goldman, P Shi, M Reck, L Paz-Ares, A Koustenis, KC Hurt Clinical lung cancer 17 (1), 80-84, 2016 | 60 | 2016 |
| JPEG compression immune steganography using wavelet transform J Xu, AH Sung, P Shi, Q Liu International Conference on Information Technology: Coding and Computing …, 2004 | 34 | 2004 |
| A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate-or high-risk diffuse large B-cell lymphoma JD Hainsworth, ER Arrowsmith, M McCleod, ED Hsi, O Hamid, P Shi, ... Leukemia & Lymphoma 57 (1), 216-218, 2016 | 31 | 2016 |
| Comparison of real-time intraoperative ultrasound-based dosimetry with postoperative computed tomography-based dosimetry for prostate brachytherapy S Nag, P Shi, B Liu, N Gupta, RR Bahnson, JZ Wang International Journal of Radiation Oncology* Biology* Physics 70 (1), 311-317, 2008 | 30 | 2008 |
| Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by … IB Vergote, R Chekerov, F Amant, P Harter, A Casado, J Emerich, ... Journal of clinical oncology 31 (25), 3127-3132, 2013 | 28 | 2013 |
| A phase III study of enzastaurin in patients with high-risk diffuse large B cell lymphoma following response to primary treatment: the Prelude trial M Crump, S Leppä, LE Fayad, JJ Lee, A Di Rocco, M Ogura, H Hagberg, ... Blood 122 (21), 371, 2013 | 27 | 2013 |
| A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma IM Ghobrial, NC Munshi, BN Harris, P Shi, NM Porter, RL Schlossman, ... American journal of hematology 86 (7), 573-578, 2011 | 26 | 2011 |
| Open‐label, single‐arm, phase II study of enzastaurin in patients with follicular lymphoma L Schwartzberg, R Hermann, I Flinn, D Flora, ED Hsi, O Hamid, P Shi, ... British journal of haematology 166 (1), 91-97, 2014 | 24 | 2014 |
| A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration … R Dreicer, J Garcia, B Rini, N Vogelzang, S Srinivas, B Somer, P Shi, ... Investigational new drugs 31, 1044-1050, 2013 | 15 | 2013 |
| In vitro determination of radiation sensitivity parameters for DU-145 prostate cancer cells JZ Wang, JG Rhee, P Shi, RD Stewart, X Allen Li International Journal of Radiation Biology 84 (6), 515-522, 2008 | 14 | 2008 |
| A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer C Clément-Duchêne, RB Natale, T Jahan, Y Krupitskaya, ... Lung Cancer 78 (1), 57-62, 2012 | 13 | 2012 |
| Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer JW Goldman, LS Rosen, AW Tolcher, K Papadopoulos, M Beeram, P Shi, ... Investigational new drugs 36, 629-637, 2018 | 11 | 2018 |
| A first-in-human phase I study of the oral p38 MAPK inhibitor LY2228820 dimesylate in patients with advanced cancer. MP Goetz, AW Tolcher, P Haluska, KP Papadopoulos, C Erlichman, ... Journal of Clinical Oncology 30 (15_suppl), 3001-3001, 2012 | 6 | 2012 |
| Phase II study of enzastaurin in patients with follicular lymphoma: updated final clinical results and immunohistochemical correlations L Schwartzberg, R Hermann, IW Flinn, D Flora, ED Hsi, O Hamid, ... Blood, The Journal of the American Society of Hematology 120 (21), 777-777, 2012 | 4 | 2012 |
| Text Steganography using Wavelet Transform J Xu, AH Sung, P Shi, Q Liu Proc. of 7th IASTED International Conference on Internet and Multimedia …, 2003 | 3 | 2003 |
| Fulvestrant (FUL) plus enzastaurin (ENZA) vs FUL plus placebo (PBO) in aromatase inhibitor (AI)-resistant metastatic breast cancer (MBC): a randomized, double-blind, phase 2 trial RS De Jong, GS Sonke, N Maass, K Mansouri, L Cirri, P Shi, O Hamid, ... Annals of Oncology 23, ix124, 2012 | 2 | 2012 |
| An open-label, randomized, phase 2 Study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate-or high-riskdiffuse large B-cell … JD Hainsworth, ER Arrowsmith, M McCleod, ED Hsi, O Hamid, P Shi, ... Leuk Lymphoma, 1-11, 2015 | | 2015 |
